Merus (NASDAQ:MRUS – Free Report) had its target price lifted by Guggenheim from $57.00 to $93.00 in a research note published on Tuesday, Benzinga reports. Guggenheim currently has a buy rating on the biotechnology company’s stock. Several other equities analysts also recently weighed in on MRUS. Stifel Nicolaus increased their price target on shares of […]
HC Wainwright reiterated their buy rating on shares of Merus (NASDAQ:MRUS – Free Report) in a research note issued to investors on Friday, Benzinga reports. HC Wainwright currently has a $65.00 price target on the biotechnology company’s stock. Several other brokerages have also recently weighed in on MRUS. William Blair restated an outperform rating on […]
Needham & Company LLC reissued their buy rating on shares of Merus (NASDAQ:MRUS – Free Report) in a report released on Friday morning, Benzinga reports. Needham & Company LLC currently has a $66.00 target price on the biotechnology company’s stock. A number of other analysts also recently commented on the company. Truist Financial started coverage […]
StockNews.com cut shares of Merus (NASDAQ:MRUS – Free Report) from a hold rating to a sell rating in a research report sent to investors on Wednesday. MRUS has been the subject of a number of other reports. HC Wainwright restated a buy rating and issued a $65.00 target price on shares of Merus in a […]
StockNews.com downgraded shares of Merus (NASDAQ:MRUS – Free Report) from a hold rating to a sell rating in a research note issued to investors on Wednesday. A number of other equities analysts also recently issued reports on the company. Truist Financial assumed coverage on Merus in a research note on Thursday, March 28th. They set […]